Compare VRXA & CGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRXA | CGC |
|---|---|---|
| Founded | N/A | N/A |
| Country | Switzerland | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.3M | 401.0M |
| IPO Year | N/A | 2023 |
| Metric | VRXA | CGC |
|---|---|---|
| Price | $1.76 | $0.92 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 951.5K | ★ 2.9M |
| Earning Date | N/A | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 84.17 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,759,000.00 |
| Revenue This Year | N/A | $8.27 |
| Revenue Next Year | N/A | $15.68 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.70 | $0.84 |
| 52 Week High | $4.50 | $2.38 |
| Indicator | VRXA | CGC |
|---|---|---|
| Relative Strength Index (RSI) | 29.98 | 41.57 |
| Support Level | $1.74 | $0.84 |
| Resistance Level | $2.29 | $1.23 |
| Average True Range (ATR) | 0.20 | 0.04 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 13.46 | 31.59 |
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.